<DOC>
	<DOCNO>NCT00375778</DOCNO>
	<brief_summary>Purpose study : To investigate whether NMDA antagonist Memantine substantial effect brain metabolism patient Parkinson 's disease ( PD ) , use Positron Emission Tomography ( PET ) . Background : Disturbances brain metabolism think contribute degeneration neuron brain PD patient . Production toxic oxygen radical presence much excitatory neurotransmitter ( glutamate ) due activity involve . These factor theoretically alleviate memantine . Hypothesis : Memantine decrease metabolism area PD brain know over-active . Decreases cerebral blood flow oxygen metabolism area consequence detect PET .</brief_summary>
	<brief_title>Parkinson 's Disease Evaluated PET Effect Memantine</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Parkinson 's Disease ( British Brain Bank Criteria ) Age 5070y Tobacco use Any serious medical condition ( Heart disease , kidney disease , liver disease , endocrinological disorder etc ) Metal implant contraindicate MR scan Drug use affect central nervous system Psychiatric disorder Head trauma disorder head , skull brain Drug addiction use kind illegal substance affect central nervous system Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Positron Emission Tomography</keyword>
	<keyword>Memantine</keyword>
	<keyword>NMDA antagonist</keyword>
	<keyword>Cerebral Blood Flow</keyword>
	<keyword>Cerebral Metabolic Rate Oxygen</keyword>
</DOC>